— Source Field Medical Division —
The human body is an electromagnetic organism. Every cell, organ, and neurological process generates measurable field signatures. Source field medical technology reads, maps, and therapeutically recalibrates these fields —
opening a new era of non-invasive psychiatric and neurological medicine.
⚠ RESEARCH & DEVELOPMENT CONCEPT — FOR CLINICAL TRIAL CONSIDERATION
0.1 Hz — 40 kHz
Field Frequency Range
Biofield Layer Detection
Scan Resolution
Cellular & Neurological
Coherence Depth
Scalar / Longitudinal Wave
Emission Type
15 — 45 Minutes
Session Duration
Psychosis · Trauma · Neurodegeneration
Target Applications
— Clinical Applications —
Biofield Disruption Mapping
Source field resonance scanning detects anomalous electromagnetic signatures in the cortical biofield — patterns consistently associated with schizophrenic and psychotic episodes. Non-invasive. No radiation. Real-time mapping of field coherence collapse.
Scalar Wave Entrainment
Targeted scalar field pulses re-entrain disrupted neurological biofields. Peer-reviewed analogues in transcranial magnetic stimulation validate the mechanism. Source field devices operate at the quantum vacuum interface — deeper penetration, zero side effects.
Emotional Field Recalibration
Traumatic memory encodes as disrupted biofield standing waves in the amygdala-hippocampal circuit. Source field therapy dissolves these incoherent patterns — analogous to EMDR but operating at the electromagnetic substrate level.
Mitochondrial Field Restoration
Alzheimer's, Parkinson's, and MS show measurable biofield entropy collapse preceding clinical symptoms by years. Source field scanning enables pre-symptomatic detection. Therapeutic entrainment restores mitochondrial coherence and slows cellular degradation.
— Scientific Foundation —
The body generates measurable electromagnetic fields at every scale — cellular, organ, and whole-body. These fields are not epiphenomenal: they carry biological information.
Longitudinal scalar waves propagate through the quantum vacuum and interact directly with biological field structures — bypassing classical EM shielding limitations.
HeartMath Institute's 30 years of research validates field-based neurological intervention. Source field therapy extends this principle to the quantum vacuum interface.
Fritz-Albert Popp's biophoton research demonstrates that cells communicate via coherent light. Source field disruption maps directly onto biophoton decoherence patterns.
Rupert Sheldrake's morphic field theory provides the theoretical framework for non-local biofield influence — directly applicable to psychiatric field mapping.
Photosynthesis, enzyme catalysis, and avian navigation all use quantum coherence. Neurological function operates at the same quantum substrate — accessible via source field intervention.
— Product Line —
Clinical desktop device for full biofield mapping. Generates a 3D coherence map of patient's electromagnetic anatomy. Integrates with standard EMR systems.
Targeted scalar field emitter for active treatment sessions. Programmable waveform libraries for specific conditions. Automated coherence feedback loop.
Patient-worn biofield sensor for 24/7 coherence tracking. Alerts clinical staff to field disruption events before behavioural symptoms manifest.
Room-scale source field amplification grid for psychiatric wards. Maintains therapeutic coherence baseline across entire clinical environment.
— Clinical Trial Roadmap —
Establish measurable biofield signatures across healthy controls vs. diagnosed psychosis patients. Validate scanner sensitivity and repeatability.
Confirm zero adverse effects across scalar field exposure protocols. Determine optimal session duration, frequency, and waveform parameters.
Randomised controlled trial measuring biofield coherence recovery, symptom reduction, and medication dependency reduction vs. standard of care.
International multi-centre trial across psychiatric institutions. Regulatory submission to Health Canada, FDA, and EMA for medical device classification.
We are seeking institutional partners, research hospitals, and bioelectromagnetics scientists to co-develop the clinical trial framework. This technology will redefine psychiatric medicine. Be part of the first wave.